长春瑞滨联合卡铂治疗晚期非小细胞肺癌临床观察.docVIP

长春瑞滨联合卡铂治疗晚期非小细胞肺癌临床观察 　［摘要］ 目的 探讨长春瑞滨联合卡铂治疗晚期非小细胞肺癌的疗效和不良反应。方法 76例经病理或细胞学确诊晚期非小细胞肺癌，行为状态(PS)为0～2进入该研究。患者被随机分成两组，治疗组：长春瑞滨25 mg/m2第1、8天，卡铂AUC为5第2天；对照组：长春瑞滨25 mg/m2第1、8天，顺铂100 mg/m2第2天，水化。每3周重复。结果 治疗组39例，CR 2例、PR 12例、SD 11例、PD 14例，总有效率CR+PR 14例(35.89%)；对照组 37例 CR 1例、PR 12例、SD 16例、PD 8例、总有效率CR+PR 13例(35.13%)，两组有效率差异无显著性(P＞0.05)。血液学毒性和恶心、呕吐两组差异有显著性(P＜0.05)。结论 长春瑞滨联合卡铂治疗晚期非小细胞肺癌的疗效相似，骨髓抑制相似；恶心和呕吐明显减轻，可以相互替代。 ［关键词］ 长春瑞滨；非小细胞肺癌；晚期；治疗效果 Clinical observation of NVB and carboplatin in the management of advanced non-small cell lung cancer ［Abstract］ Objective To evaluate the activity and toxicity of carboplatin and or/and cisplatin in the management of advanced non-small cell lung cancer.Methods Seventy patients with pathological or cytological diagnosis of NSCLC，measurable lesions，and PS 0～2 were enrolled.Thirty patients were administered NVB 25 mg/m2 and carboplatin AUC 5;37 patients were administered NVB 25 mg/m2 and cisplatin 100 mg/m2 for 3 weeks.Results All patients were assessable for response，toxicity and survival.Complete response was observed in 2 cases，partial response in 12，stable in 11，progressive in 14 and overall response rate in 14(35.89%) and complete response was observed in 1 case，partial response in 12，stable in 16，progressiiv in 8，and overall response rate 35.13% (P＞0.05) respectively.The hematological toxicity were seen in NVB and carboplatin group’’nausea and vomiting in NVB and cisplatin group (P＜0.05).Conclusion The activity of NVB and carboplatin was similar to NVB and cisplatin in the management of advanced non-small cell lung cancer and more hematological toxicities had been seen in carboplatin regimen，and more nausea and vomiting had been seen in carboplatin regime. ［Key words］ NVB；non-small lung cancer;advanced;therapeutic effects 长春瑞滨联合顺铂是治疗晚期非小细胞肺癌的主要化疗方案，恶心和呕吐是其影响患者生存质量的主要因素。我科于2000年10月～2005年4月用卡铂替代顺铂联合长春瑞滨用于治疗晚期非小细胞肺癌进行对照研究，现将结果报告如下。 1 资料与方法 1.1 一般资料 2000年10月～2005年4月经病理或细胞学确诊为晚期非小细胞肺癌，一般状态好、行为状态评分(PS)为0～2，有可评价疗效的客观指标，预期生存期3个